Allobarbital

Allobarbital

Clinical data
Other names	5,5-Diallylbarbituric acid, Allobarbital
ATC code	N05CA21 (WHO)
Legal status
Legal status	CA: Schedule IV DE: Anlage III (Special prescription form required) US: Schedule III
Identifiers
IUPAC name 5,5-di(prop-2-en-1-yl)-1,3-diazinane-2,4,6-trione
CAS Number	52-43-7 Y
PubChem CID	5842
ChemSpider	5635 Y
UNII	8NT43GG2HA
KEGG	D02817 Y
ChEMBL	ChEMBL267719 Y
CompTox Dashboard (EPA)	DTXSID9022572
ECHA InfoCard	100.000.129
Chemical and physical data
Formula	C10H12N2O3
Molar mass	208.217 g·mol−1
3D model (JSmol)	Interactive image
SMILES O=C1NC(=O)NC(=O)C1(C\C=C)C\C=C
InChI InChI=1S/C10H12N2O3/c1-3-5-10(6-4-2)7(13)11-9(15)12-8(10)14/h3-4H,1-2,5-6H2,(H2,11,12,13,14,15) Y Key:FDQGNLOWMMVRQL-UHFFFAOYSA-N Y
(verify)

Allobarbital, also known as allobarbitone and branded as Dial, Cibalgine (in combination with aminophenazone), or Dial-Ciba (in combination with ethyl carbamate), is a barbiturate derivative invented in 1912 by Ernst Preiswerk and Ernst Grether working for CIBA. It was used primarily as an anticonvulsant although it has now largely been replaced by newer drugs with improved safety profiles. Other uses for allobarbital included as an adjutant to boost the activity of analgesic drugs, and use in the treatment of insomnia and anxiety.

Allobarbital was never particularly widely used compared to better known barbiturates such as phenobarbital and secobarbital, although it saw more use in some European countries such as Bulgaria and Slovakia, and is still used in for example Poland, but only as compound.